Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Favezelimab/pembrolizumab - Merck Sharp & Dohme

Next Previous
Drug Profile

Favezelimab/pembrolizumab - Merck Sharp & Dohme

Alternative Names: Coformulation favezelimab/pembrolizumab - Merck Sharp & Dohme; Mavezelimab/pembrolizumab - Merck Sharp & Dohme; MK 4280A; MK-4820A; Pembrolizumab/favezelimab - Merck Sharp & Dohme

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bladder cancer; Colorectal cancer; Endometrial cancer; Hodgkin's disease; Malignant melanoma; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 21 Mar 2025 Merck Sharp & Dohme completes the phase III MK-4280A-007 trial in Colorectal cancer (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in Australia, Canada, Chile, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Malaysia, Norway, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine, the UK and US (IV) (NCT05064059)
  • 21 Feb 2025 Merck Sharp & Dohme completes the phase-III KEYFORM-007 trial in Colorectal cancer (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, In adults, In the elderly) in China (IV, Infusion) (NCT05600309)
  • 16 Dec 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in China (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top